Dr. Merchan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1611 NW 12th Ave
Miami, FL 33136Phone+1 305-585-1111
Education & Training
Harvard University - Massachusetts Institute of TechnologyMMSc, Translational Research, 2001 - 2003
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1994 - 1998
Universidad Catolica de Santiago de GuayaquilClass of 1992
Certifications & Licensure
FL State Medical License 1997 - 2026
MN State Medical License 2003 - 2007
MA State Medical License 1998 - 2005- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors Start of enrollment: 2008 Nov 01
- Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy Start of enrollment: 2016 Jan 05
- Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors Start of enrollment: 2017 Apr 17
Publications & Presentations
PubMed
- 19 citationsLenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase...Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald
Journal of Clinical Oncology. 2024-04-10 - A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen
Future Oncology. 2024-03-01 - 5 citationsPhase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, Elizabeth R Plimack, Jaime R Merchan
European Journal of Cancer. 2024-01-01
Journal Articles
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
Lectures
- Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Other
- Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiencyMerchan JR
http://www.uptodate.com/contents/chemotherapy-related-nephrotoxicity-and-dose-modification-in-patien
UpToDate, Wolters Kluwer Health - 2013-02-05
Authored Content
- Notch Pathway Inhibition with LY3039478 in Soft Tissue Sarcoma and Gastrointestinal Stromal TumoursOctober 2018
Press Mentions
Sylvester Junior Faculty Selected for K12 Research GrantsMay 16th, 2023- Sylvester’s Course on Cancer Clinical Trials Goes National, InternationalFebruary 15th, 2023
- A Boost for Sylvester: DeSantis Announces $100 Million in Funding for State’s Top Cancer CentersMay 18th, 2022
- Join now to see all
Grant Support
- Tumor And Stromal Targeting By Oncolytic VirusesNational Cancer Institute2011–2012
- Biomarkers For VEGF And Mtor Blockade In Advanced Renal CancerNational Cancer Institute2006–2007
Professional Memberships
- Member
- Member
Other Languages
- Spanish, Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
